Profile data is unavailable for this security.
About the company
Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
- Revenue in USD (TTM)0.00
- Net income in USD-40.42m
- Incorporated2006
- Employees26.00
- LocationProtara Therapeutics Inc345 Park Avenue South, 3Rd FloorNEW YORK 10010United StatesUSA
- Phone+1 (646) 844-0337
- Fax+1 (302) 655-5049
- Websitehttps://protaratx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annovis Bio Inc | 0.00 | -56.20m | 57.04m | 6.00 | -- | -- | -- | -- | -6.12 | -6.12 | 0.00 | -0.7368 | 0.00 | -- | -- | 0.00 | -243.15 | -106.31 | -328.17 | -124.71 | -- | -- | -- | -- | -- | -4.03 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
| Cidara Therapeutics Inc | 63.91m | -22.93m | 57.07m | 69.00 | -- | -- | -- | 0.893 | -0.2528 | -0.2528 | 0.7136 | -0.0906 | 1.12 | -- | 5.79 | 926,159.40 | -40.05 | -65.23 | -804.74 | -154.37 | 45.03 | -- | -35.88 | -100.61 | 0.8122 | -- | -- | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
| Eagle Pharmaceuticals Inc | 257.55m | 11.95m | 57.27m | 134.00 | 4.84 | 0.2291 | 1.75 | 0.2224 | 0.911 | 0.911 | 19.59 | 19.25 | 0.6549 | 1.55 | 2.56 | 1,922,022.00 | 3.04 | 6.37 | 4.04 | 7.98 | 69.84 | 71.86 | 4.64 | 7.85 | 1.67 | 3.55 | 0.2178 | 0.00 | 84.56 | 5.99 | 513.14 | -8.42 | -49.05 | -- |
| Reneo Pharmaceuticals Inc | 0.00 | -77.39m | 58.15m | 8.00 | -- | 0.6563 | -- | -- | -2.52 | -2.52 | 0.00 | 2.65 | 0.00 | -- | -- | 0.00 | -71.78 | -- | -81.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
| Equillium Inc | 36.08m | -13.34m | 58.88m | 44.00 | -- | 2.61 | -- | 1.63 | -0.3845 | -0.3845 | 1.04 | 0.6403 | 0.5597 | -- | 10.98 | 820,090.90 | -20.68 | -46.81 | -38.46 | -57.36 | -- | -- | -36.96 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 59.28m | 217.00 | -- | 0.4376 | -- | 18.65 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -40.33m | 59.80m | 20.00 | -- | 0.6995 | -- | -- | -1.82 | -1.82 | 0.00 | 3.45 | 0.00 | -- | -- | 0.00 | -44.35 | -38.44 | -47.03 | -39.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 54.16 | -- | -- | -- |
| Protara Therapeutics Inc | 0.00 | -40.42m | 59.88m | 26.00 | -- | 0.4841 | -- | -- | -3.57 | -3.57 | 0.00 | 6.01 | 0.00 | -- | -- | 0.00 | -42.05 | -37.02 | -44.82 | -38.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.71 | -- | -17.67 | -- |
| Moolec Science SA | 2.65m | -52.66m | 60.36m | 45.00 | -- | 5.96 | -- | 22.82 | -1.44 | -1.44 | 0.0766 | 0.2367 | -- | -- | -- | 58,780.00 | -- | -- | -- | -- | 2.92 | -- | -1,990.79 | -- | 0.2243 | -0.1889 | 0.2372 | -- | -- | -- | -1,044.02 | -- | -- | -- |
| Kronos Bio Inc | 6.29m | -112.67m | 61.30m | 62.00 | -- | 0.378 | -- | 9.75 | -1.95 | -1.95 | 0.1089 | 2.70 | 0.0248 | -- | -- | 101,419.40 | -44.34 | -35.47 | -48.77 | -37.14 | -- | -- | -1,791.87 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
| Aligos Therapeutics Inc | 15.53m | -87.68m | 61.30m | 66.00 | -- | 0.6657 | -- | 3.95 | -1.82 | -1.82 | 0.3204 | 1.22 | 0.1041 | -- | -- | 235,287.90 | -58.80 | -51.20 | -72.71 | -59.73 | -- | -- | -564.61 | -1,399.21 | -- | -- | 0.0026 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
| Calcimedica Inc | 0.00 | -34.36m | 61.65m | 14.00 | -- | 4.01 | -- | -- | -26.09 | -26.09 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -132.51 | -63.99 | -155.72 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
| Immix Biopharma Inc | 0.00 | -15.43m | 62.03m | 14.00 | -- | 2.85 | -- | -- | -0.8803 | -0.8803 | 0.00 | 0.8235 | 0.00 | -- | -- | 0.00 | -89.54 | -- | -103.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
| RetinalGenix Technologies Inc | 0.00 | -2.09m | 62.25m | 0.00 | -- | -- | -- | -- | -0.1205 | -0.1205 | 0.00 | -0.0797 | 0.00 | -- | -- | -- | -929,284.40 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -543.50 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
| Kezar Life Sciences Inc | 7.00m | -101.87m | 62.42m | 58.00 | -- | 0.3327 | -- | 8.92 | -1.40 | -1.40 | 0.0965 | 2.58 | 0.0269 | -- | -- | 120,689.70 | -39.12 | -32.54 | -41.41 | -34.09 | -- | -- | -1,455.29 | -4,308.11 | -- | -- | 0.051 | -- | -- | -- | -49.28 | -- | 10.08 | -- |
Data as of May 06 2024. Currency figures normalised to Protara Therapeutics Inc's reporting currency: US Dollar USD
65.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Opaleye Management, Inc.as of 31 Dec 2023 | 2.69m | 23.55% |
| RA Capital Management LPas of 10 Apr 2024 | 1.90m | 16.62% |
| Citadel Advisors LLCas of 10 Apr 2024 | 1.20m | 10.53% |
| Heights Capital Management, Inc.as of 05 Apr 2024 | 600.38k | 5.25% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 424.97k | 3.72% |
| Baker Bros. Advisors LPas of 31 Dec 2023 | 199.67k | 1.75% |
| Ikarian Capital LLCas of 31 Dec 2023 | 188.66k | 1.65% |
| Privium Fund Management (UK) Ltd.as of 31 Mar 2024 | 119.73k | 1.05% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 113.30k | 0.99% |
| Geode Capital Management LLCas of 31 Dec 2023 | 78.52k | 0.69% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
